XELJANZ (Pfizer Laboratories Div Pfizer Inc)
Welcome to the PulseAid listing for the XELJANZ drug offered from Pfizer Laboratories Div Pfizer Inc. This Janus Kinase Inhibitor [EPC],Janus Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Pfizer Laboratories Div Pfizer Inc |
| NON-PROPRIETARY NAME: | tofacitinib |
| SUBSTANCE NAME: | TOFACITINIB CITRATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Janus Kinase Inhibitor [EPC],Janus Kinase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2012-11-09 |
| END MARKETING DATE: | 0000-00-00 |
XELJANZ HUMAN PRESCRIPTION DRUG Details:
| Item Description | XELJANZ from Pfizer Laboratories Div Pfizer Inc |
| LABELER NAME: | Pfizer Laboratories Div Pfizer Inc |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5(mg/1) |
| START MARKETING DATE: | 2012-11-09 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0069-1001_022fd1b8-4c93-4f7c-9a61-8958386c9483 |
| PRODUCT NDC: | 0069-1001 |
| APPLICATION NUMBER: | NDA203214 |
Other TOFACITINIB CITRATE Pharmaceutical Manufacturers / Labelers:
